Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens
Abstract
Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to respond to therapy. This demonstrates the need for techniques capable of providing personalized feedback about treatment response at the earliest stages of therapy to identify patients likely to benefit from changing treatment. Diffuse optical spectroscopic imaging (DOSI) has emerged as a promising functional imaging technique for NAC monitoring. DOSI uses non-ionizing near-infrared light to provide non-invasive measures of absolute concentrations of tissue chromophores such as oxyhemoglobin. In 2011, we reported a new DOSI prognostic marker, oxyhemoglobin flare: a transient increase in oxyhemoglobin capable of discriminating NAC responders within the first day of treatment. In this follow-up study, DOSI was used to confirm the presence of the flare as well as to investigate whether DOSI markers of NAC response are regimen dependent.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 13, 2020
- Source ID
- 10.1186/s13058-020-01262-1
Entities
People
- Anais Leproux
- Anup Tank
- Bruce J. Tromberg
- Darren Roblyer
- Eric W. Jones
- Hannah M. Peterson
- Howard Cabral
- Naomi Ko
- Rita S. Mehta
- Syeda Tabassum
- Thomas O'Sullivan
- Vivian Pera
Organizations
- American Cancer Society
- Chao Family Comprehensive Cancer Center
- National Cancer Institute
- National Institutes of Health
- United States Department of Defense